Hsp90 inhibitors and drugs from fragment and virtual screening

Topics in Current Chemistry

Volumn 317, Issue , 2012, Pages 61-82

  Roughley, Stephen ^a   Wright, Lisa ^a   Brough, Paul ^a   Massey, Andrew ^a   Hubbard, Roderick E ^a,b  

^a Vernalis PLC   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Fragment based drug discovery; Hsp90; SAR by catalogue; Structure based drug discovery; Virtual screening

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HSP90 HEAT-SHOCK PROTEINS; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858146937     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128-2011-181     Document Type: Article

References (57)

1. Dutta D et al (2009) The molecular chaperone heat shock protein-90 positively regulates rotavirus infectionx. Virology 391(2):325-333
2. Dollins DE et al (2007) Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 28(1):41-56 (Pubitemid 47531972)
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70 (Pubitemid 30046295)
4. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761-772 (Pubitemid 41400776)
5. Trepel J et al (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537-549
6. Supko JG et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315
7. Soga S, Shiotsu Y, Akinaga S, Sharma SV (2003) Development of radicicol analogues. Curr Cancer Drug Targets 3(5):359-369 (Pubitemid 37128322)
8. Gao Z, Garcia-Echeverria C, Jensen MR (2010) Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Dev 13(2):193-202
9. Taldone T et al (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8(4):370-374
10. Eccles SA et al (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8):2850-2860 (Pubitemid 351556284)
11. Brough PA et al (2008) 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51(2):196-218
12. Lundgren K et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 8(4):921-929
13. Wang Y et al (2010) STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 11(12):1466-1476
14. Huang KH et al (2009) Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52(14):4288-4305
15. Woodhead AJ et al (2010) Discovery of (2,4-dihydroxy-5-isopropylphenyl)- [5-(4-methylpiperazin-1-ylmethyl)-1,3-di hydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 53(16): 5956-5969
16. Biamonte MA et al (2010) Heat shock protein 90: inhibitors in clinical trials. J Med Chem 53(1):3-17
17. Brough PA et al (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d] pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 52(15):4794-4809
18. Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271-294 (Pubitemid 44118034)
19. Wright L et al (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 11(6):775-785 (Pubitemid 38836894)
20. Chiosis G et al (2003) Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 3(5):371-376 (Pubitemid 37128323)
21. Obermann WM et al (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143(4):901-910 (Pubitemid 28547391)
22. Leach AR, Shoichet BK, Peishoff CE (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49(20):5851-5855 (Pubitemid 44484931)
23. Warren GL et al (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49(20):5912-5931 (Pubitemid 44484938)
24. Barril X, Morley SD (2005) Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J Med Chem 48(13):4432-4443 (Pubitemid 40884945)
25. Baurin N et al (2004) Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J Chem Inf Comput Sci 44(2):643-651
26. Irwin JJ, Shoichet BK (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45(1):177-182 (Pubitemid 40736970)
27. Stebbins CE et al (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89(2):239-250 (Pubitemid 27199896)
28. Morley SD, Afshar M (2004) Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock. J Comput Aided Mol Des 18(3):189-208 (Pubitemid 39069414)
29. Aherne W et al (2003) Assays for HSP90 and inhibitors. Methods Mol Med 85:149-161
30. Brough PA et al (2005) 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4- carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett 15(23):5197-5201 (Pubitemid 41463646)
31. Cheung KM et al (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 15(14):3338-3343
32. Howes R et al (2006) A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 350(2):202-213 (Pubitemid 43332820)
33. Barril X et al (2005) Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 15(23):5187-5191 (Pubitemid 41463644)
34. Murray CW et al (2010) Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 53(16):5942-5955
35. Panaretou B et al (2002) Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10(6):1307-1318 (Pubitemid 36050873)
36. Baurin N et al (2004) Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 44(6):2157-2166
37. Hubbard RE et al (2007) The SeeDs approach: integrating fragments into drug discovery. Curr Top Med Chem 7(16):1568-1581 (Pubitemid 350131015)
38. Congreve M et al (2008) Recent developments in fragment-based drug discovery. J Med Chem 51(13):3661-3680 (Pubitemid 351956496)
39. Fischer M, Hubbard RE (2009) Fragment-based ligand discovery. Mol Interv 9(1):22-30
40. Schulz MN, Hubbard RE (2009) Recent progress in fragment-based lead discovery. Curr Opin Pharmacol 9(5):615-621
41. Shuker SB et al (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274(5292):1531-1534 (Pubitemid 26403929)
42. Huth JR et al (2007) Discovery and design of novel HSP90 inhibitors using multiple fragmentbased design strategies. Chem Biol Drug Des 70(1):1-12 (Pubitemid 47057425)
43. Oltersdorf T et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677-681 (Pubitemid 40825512)
44. Hajduk PJ (2006) SAR by NMR: putting the pieces together. Mol Interv 6(5):266-272 (Pubitemid 44556047)
45. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6(3):211-219 (Pubitemid 46344625)
46. Howard N et al (2006) Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J Med Chem 49(4):1346-1355 (Pubitemid 43271886)
47. Barker JJ et al (2010) Discovery of a novel Hsp90 inhibitor by fragment linking. ChemMed-Chem 5(10):1697-1700
48. Barker JJ et al (2009) Fragment-based identification of Hsp90 inhibitors. ChemMedChem 4 (6):963-966
49. Dymock BW et al (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48(13):4212-4215 (Pubitemid 40884922)
50. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5(9):730-739 (Pubitemid 44323700)
51. Chiosis G, Neckers L (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 1(5):279-284
52. Hubbard RE (2008) Fragment approaches in structure-based drug discovery. J Synchrotron Radiat 15(Pt 3):227-230 (Pubitemid 351571008)
53. Massey AJ et al (2010) Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 9(4):906-919
54. Fadden P et al (2010) Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 17(7):686-694
55. Hubbard RE, Murray JB (2011) Experiences in fragment-based lead discovery. Methods Enzymol 493:509-531
56. Dymock B et al (2004) Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg Med Chem Lett 14(2):325-328 (Pubitemid 38045115)
57. Roughley SD, Hubbard RE (2011) How well can fragments explore accessed chemical space? A case study from Heat Shock Protein 90. J Med Chem. DOI: 10.1021/jm200350g